The multicenter phase II Panphila trial reported a pCR rate of 55.1% in 69 patients with HER2-positive BC receiving six cycles of neoadjuvant therapy with TCbHPy (docetaxel, carboplatin, trastuzumab, pyrotinib) [74]. This evidence concerns the gene ERBB2 and breast cancer.